FPMI (FluoroPharma Medical) Scaled Net Operating Assets: -11.32 (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Scaled Net Operating Assets?

FluoroPharma Medical FPMI Scaled Net Operating Assets is -11.32 as of Dec. 2016.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

FluoroPharma Medical's operating assets for the quarter that ended in Dec. 2016 was $0.31 Mil. FluoroPharma Medical's operating liabilities for the quarter that ended in Dec. 2016 was $4.69 Mil. FluoroPharma Medical's Total Assets for the quarter that ended in Sep. 2016 was $0.39 Mil. Therefore, FluoroPharma Medical's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2016 was -11.32.


FluoroPharma Medical Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Scaled Net Operating Assets Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 -1.76 -1.55 -4.64 -5.22

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -5.32 -11.41 -5.60 -11.32

FPMI vs HSTC, OBMPD, GOVX: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Scaled Net Operating Assets falls into.



FluoroPharma Medical Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

FluoroPharma Medical's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2016 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2016 )
=(Operating Assets (A: Dec. 2016 )-Operating Liabilities (A: Dec. 2016 ))/Total Assets (A: Dec. 2015 )
=(0.31-4.689)/0.839
=-5.22

where

Operating Assets(A: Dec. 2016 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.335 - 0.025
=0.31

Operating Liabilities(A: Dec. 2016 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10.514 - 0 - 5.825
=4.689

FluoroPharma Medical's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2016 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2016 )
=(Operating Assets (Q: Dec. 2016 )-Operating Liabilities (Q: Dec. 2016 ))/Total Assets (Q: Sep. 2016 )
=(0.31-4.689)/0.387
=-11.32

where

Operating Assets(Q: Dec. 2016 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.335 - 0.025
=0.31

Operating Liabilities(Q: Dec. 2016 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10.514 - 0 - 5.825
=4.689

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -11.32 mean?
FluoroPharma Medical (FPMI) has a Scaled Net Operating Assets of -11.32 as of Dec. 2016. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Scaled Net Operating Assets too high?
FluoroPharma Medical's current Scaled Net Operating Assets is -11.32.
How does FluoroPharma Medical's Scaled Net Operating Assets compare to HSTC and OBMPD?
FluoroPharma Medical's Scaled Net Operating Assets of -11.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on FluoroPharma Medical and its competitors. FluoroPharma Medical's current Scaled Net Operating Assets is -11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Scaled Net Operating Assets of -11.32. The current Scaled Net Operating Assets is -11.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Scaled Net Operating Assets is -11.32 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.